Predicting and Defining Vancomycin Efficacy: Program Overview
CME ARTICLE • CID
Course Faculty Disclosures 0 1
0 Disclosure policy. It is the policy of Boston University School of Medicine, Department of Continuing Medical Education, that faculty disclose to program participants any real or ap- parent conflict of interest. In addition, faculty are asked to disclose when any unapproved use of pharmaceuticals and de- vices is being discussed. Authors. Robert C. Moellering , Jr., MD (Chairman , De- partment of Medicine, Beth Israel Deaconess Medical Center , Boston, MA), is a consultant to Aventis, Cubist, Pfizer , and Vicuron and serves on the speakers' bureaus of Aventis, Cubist, and Pfizer. Dr. Moellering does not discuss unlabeled/investi- gational uses of a commercial product. Patrice Courvalin, MD (Professor and Head, Antibacterial Agents Unit, National Reference Center for Antibiotics, Institut
1 Robert C. Moellering, Jr., Patrice Courvalin, Ronald N. Jones , Donald P. Levine, Michael J. Rybak, Dennis L. Stevens, and George Sakoulas
Release and Expiration Dates Release date: 1 January 2006. Expiration date: 1 January 2009.
-
CME INFORMATION AND INSTRUCTIONS
Accreditation
Boston University School of Medicine is accredited by the
Accreditation Council for Continuing Medical Education to
provide continuing medical education (CME) for physicians.
Boston University School of Medicine designates this
educational activity for a maximum of 3 category 1 credits toward
the American Medical Association Physician’s Recognition
Award. Physicians should claim only those credits that they
actually spent in the activity.
To successfully complete this activity, participants are
required to read the entire supplement and complete and submit
the test answer sheet by 1 May 2008. CME credit will be
awarded if a score of 70% or better is achieved. A certificate
of credit will be sent within 6 weeks of receipt of the test answers
to those participants who successfully complete the test.
The estimated time to review the supplement and complete
the accompanying test is 3 hours.
Target Audience
This educational activity is intended for infectious diseases
specialists.
Educational Needs
Participants will gain insight into the treatment of patients with
infections caused by strains of methicillin-resistant
Staphylococcus aureus (MRSA). For many years, vancomycin has been
the standard of care for treating infections caused by MRSA
pathogens. However, since the 1990s, resistance to vancomycin
has emerged among MRSA strains; thus, understanding the
optimal clinical application of vancomycin is of great
importance.
Educational Objectives
At the conclusion of this activity, participants will be able to
1. discuss the pharmacokinetics and pharmacodynamics of
vancomycin and the clinical implications of its use,
2. describe the potential molecular mechanisms of bacterial
resistance to antibiotic agents, and
3. illustrate the methodologies used to test resistance and
susceptibility to vancomycin in bacteria, as well as the drawbacks
and the clinical implications thereof.
Grant Support
This educational activity is supported by an unrestricted grant
from Cubist Pharmaceuticals.
Disclaimer
This CME program is intended solely for educational purposes
for qualified health care professionals. In no event shall Boston
University be liable for any decision made or action taken in
reliance on the information contained in the program. In no
event should the information contained in the program be used
as a substitute for professional care. No physician-patient
relationship is being established.
Pasteur, Paris, France), is a consultant to Sanofi-Synthelabo
and Grunenthal. Dr. Courvalin does not discuss unlabeled/
investigational uses of a commercial product.
Ronald N. Jones, MD (Professor [Adjunct] of Medicine,
Tufts University School of Medicine, Boston, MA), is President
and CEO of JMI Laboratories (The JONES Group). He has
received grant and/or research support from AB BIODISK,
Abbott, Arpida, AstraZeneca, Basilea, Bayer, BD Microbiology
Systems, Boehringer-Ingelheim, Bristol-Myers Squibb, Centers for
Disease Control and Prevention, Cognigen, Cubist, Daiichi,
Elan (Dura), Elanco, Gensoft, GlaxoSmithKline, Intrabiotics,
LG Health Sciences, Micrologix Biotech, MicroScan, Novartis,
Peninsula, Pfizer, Pharmacia, Schering-Plough, Sequoia, TREK,
Unimed, Vicuron (Versicor), and Wyeth. Dr. Jones does not
discuss unlabeled/investigational uses of a commercial product.
Donald P. Levine, MD (Chief, Division of General Internal
Medicine, Wayne State University, Detroit, MI), has received
grant and/or research support from Cubist, Nabi, and Wyeth
and is a consultant to Cubist. Dr. Levine does not discuss
unlabeled/investigational uses of a commercial product.
Michael J. Rybak, PharmD (Associate Dean for Research,
Professor of Pharmacy and Medicine, Director, Anti-Infective
Research Laboratory, Eugene Applebaum College of Pharmacy
and Health Science, Wayne State University, Detroit, MI), has
received (...truncated)